SoftBank, Synchronoss and TBCASoft Partner on a Proof of Concept for an RCS and Blockchain-Based Mobile Payments Service
SoftBank Corp., a Japan-based telecom carrier; Synchronoss Technologies, Inc. (SNCR), a global leader and innovator of cloud, messaging, digital and IoT products; and TBCASoft, Inc., an innovator of cross-carrier blockchain platform technology, today announced that they have partnered on a Proof of Concept (PoC) for a new cross-carrier mobile payments service based on the Rich Communications Service (RCS) global messaging standard and TBCASoft’s cross-carrier blockchain platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180911005882/en/
Synchronoss has delivered in Japan, a rich and secure multi-channel communications platform, which covers SMS, email and RCS. The platform launched earlier this year. TBCASoft has been working with SoftBank, under the Carrier Blockchain Study Group (CBSG) Consortium, to deliver a cross-carrier blockchain platform called CCPS (Cross-Carrier Payment Service), which facilitates global mobile payment services among global telecommunication carriers.
The three companies have successfully completed a mobile payments service PoC that is designed to allow users to make a range of in-store, mobile and digital purchases directly from their device. A mobile customer based in Japan, for example, can travel to the USA and make a purchase in dollars via RCS which is supported by SoftBank and Synchronoss. The RCS global messaging standard can also be conveniently used to send a payment. The flexibility of the CCPS blockchain API enables the recipient to use an RCS-based messaging app or legacy messaging service like SMS or mobile email, to receive person-to-person (P2P) money transfers through the RCS wallet app either in the same country or overseas.
Commenting on the announcement, Takeshi Fukuizumi, Vice President of Softbank Corp. said: “This RCS and blockchain based mobile payments PoC demonstrates the value operator-led services can deliver. Not only do we foresee our new mobile payment service empowering merchants to operate digitally, and at a scale that was previously only available to big brands, but it will also give our customers more flexibility when it comes to their purchasing and travelling habits.”
Also commenting on the news, Synchronoss CEO and President Glenn Lurie said: “Our PoC demonstrates how SoftBank is at the forefront in bringing to market new cutting edge technology through the use of blockchain as well as new RCS-based mobile services, which will disrupt the current messaging and payments market, creating new opportunities for customers, brands, and businesses – and which will also drive incremental revenue for operators from messaging. RCS messaging will become the foundation for a new, feature-rich marketplace for brands and merchants, both large and small, to interact with subscribers. With our expertise and global reach across multiple messaging platforms – not only RCS, but also email, IM, MMS and SMS, Synchronoss is ideally positioned to take advantage of this important new trend in mobile.”
“Increasing numbers of Communication Service Providers (CSPs) are turning to blockchain technology to support a growing range of new features and services – including secured clearing and settlement, personal authentication, and IoT applications,” said Ling Wu, Founder and CEO of TBCASoft. “In today’s digital economy, blockchain lets CSPs create new services and then extend them globally, beyond their established territories and markets, in a way that’s efficient and secure. The success of this PoC proves that our Cross-Carrier Blockchain Platform can help CSPs leverage common standards like RCS to deliver disruptive services to their customers.”
SoftBank, Synchronoss and TBCASoft will demonstrate this successful mobile payments service PoC at the Mobile World Congress Americas conference, which takes place from September 12 through 14 in Los Angeles, CA.
- ENDS -
About SoftBank Corp.
SoftBank Corp., a subsidiary of SoftBank Group Corp. (TOKYO:9984), provides mobile communication, fixed-line communication, and Internet connection services to consumers and corporate customers in Japan. Leveraging the innovative technologies of other SoftBank Group companies, SoftBank Corp. is also expanding into AI, smart robotics, IoT, FinTech, cloud security and other business sectors. To learn more, please visit www.SoftBank.jp/en/corp/group/sbm/.
About Synchronoss Technologies, Inc.
Synchronoss (NASDAQ:SNCR) transforms the way companies create new revenue, reduce costs and delight their subscribers with cloud, messaging, digital and IoT products and platforms supporting hundreds of millions of subscribers across the globe. Synchronoss’ secure, scalable and groundbreaking new technologies, trusted partnerships and talented people change the way TMT customers grow their businesses. For more information, visit us at www.synchronoss.com.
About TBCASoft, Inc.
TBCASoft is a U.S.-based company developing innovative blockchain technology specifically for telecommunication carriers. Its consortium-based blockchain platform enables telecommunication carriers to create innovative services for their subscribers under a more secure, robust, and efficient environment. TBCASoft is located in Sunnyvale, California, the center of Silicon Valley. To learn more, please visit TBCASoft at www.tbcasoft.com.
For SoftBank Corp.
SoftBank Corp. Corporate Communications (Japan)
For Synchronoss Technologies, Inc.
Brian Denyeau, +1 646-277-1251
CCgroup (North America and International)
Sarah Walker / Anais Merlin, +44 20 3824 9200
For TBCASoft, Inc.
TBCASoft, Inc. (USA)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Source Photonics Announces a Comprehensive Portfolio of 50Gb/s Optical Transceivers for 5G Mid-Haul Applications23.9.2019 02:48:00 EEST | Press release
Source Photonics, a market leader of optical transceivers for wireless applications, announces a comprehensive portfolio of 50Gb/s products serving 5G mid-haul applications. Source Photonics’ product portfolio leverages 30 years of high-speed optical transceiver development and high-volume shipments into wireless, datacenter and routing applications, resulting in a broad portfolio of optical transceivers supporting data rates ranging from 125Mb/s to 400Gb/s and transmitting between 300m and 40 km. Source Photonics has leveraged early investments in signal integrity, firmware development, and uncooled high speed DML packaging to release the industry’s most broad 50G product portfolio. 50Gb/s, selected as the mid-haul data rate, provides mid-haul bandwidth requirements not supported by 25Gb/s while also offering meaningful economic advantages over traditional 100Gb/s transceivers. Furthermore, 50Gb/s data rate products support bi-directional applications, where fiber availability is scar
Celltrion Healthcare Receives CHMP Positive Opinion for Novel Subcutaneous Formulation of CT-P13 (biosimilar infliximab) for the Treatment of People With Rheumatoid Arthritis23.9.2019 02:01:00 EEST | Press release
Celltrion Healthcare today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for CT-P13 SC for marketing authorisation in the European Union (EU) in people with rheumatoid arthritis (RA). CT-P13 SC is the subcutaneous version of Remsima® (biosimilar infliximab, CT-P13). This recommendation will now be reviewed by the European Commission, which has the authority to approve medicines in the EU. A subcutaneous formulation has the potential to enhance treatment options for the use of biosimilar infliximab by providing high consistency in drug exposure and a convenient method of administration.1,2 “Today’s positive CHMP opinion brings us one step closer to providing a personalised treatment approach for people living with rheumatoid arthritis. This marks an important milestone for our business providing people with a new route of administration, and a novel formulation of infliximab,” said Hyoung-Ki
Source Photonics Demonstrates a Full 400G Product Portfolio at ECOC 201923.9.2019 02:01:00 EEST | Press release
Source Photonics, a leading vendor of optical connectivity products for Access and Datacom applications, will demonstrate its complete 400G portfolio with industry partners at ECOC 2019 from September 23-25. Source Photonics has added a wide range of new products to its industry leading portfolio of single-mode products for datacenter and routing applications. The new products leverage the company’s multi-year investment in 28Gbaud and 53Gbaud PAM4 technology and support 400G applications for reaches from 500m up to 40km in small form factor transceivers. Source Photonics’ portfolio of Datacenter and Routing products includes: 400G-DR4 supporting 400GE links over 500m as well as an enhanced reach of up to 2 km (4x100G-FR) with support for breakout into 100G-DR/FR 400G-LR8 supporting 400GE links up to 10 km 400G-ER8 supporting 400GE links up to 40km as technology demonstration “Successful interoperability between optical transceivers and hosts is crucial to rolling out the next higher d
Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)20.9.2019 19:30:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents results from the matching-adjusted indirect comparison (MAIC) of cabozantinib (Cabometyx®) versus regorafenib (Stivarga®) for the second-line treatment (2L) of patients with advanced hepatocellular carcinoma (aHCC) who received sorafenib as the only prior systemic therapy. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that cabozantinib offers greater efficacy versus regorafenib. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that in the 2L CELESTIAL sub-population who had received sorafenib as the only prior systemic therapy, cabozantinib significantly improved progression-free survival (PFS), with an additional 2.4 months provided vs. regorafenib (5.6 months vs. 3.2 months [95% confidence interval (CI): 4.90-7.26], p<0.05). Median overall survival (OS) was also favorable with cabozantinib (11.4 months vs. 10.8 months), though statistical significance was not met
RoboSense RS-LiDAR-M1 Smart LiDAR Sensor Wins AutoSens Awards 201920.9.2019 16:30:00 EEST | Press release
On September 18, 2019, RoboSense announced at Brussels, Belgium that its flagship product RS-LiDAR-M1 Smart LiDAR Sensor has been awarded the elite AutoSens Awards trophy in the “Best Automotive Safety System” category, given to only the highest-rated innovative product or technology in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005309/en/ Robosense Along With Other Winnners At The Autosens Awards Ceremony At Brussels, Belgium (Photo: Business Wire) True autonomous driving requires human-like advanced sensing of the environment for driving with little or no human input. The safety of passengers and passers-by is always the priority concern for autonomous driving. When the RS-LiDAR-M1 is integrated into the current autonomous driving car perception system, it overcomes the weaknesses of millimeter wave radar and camera technologies on identifying obstacles, and eliminates car accidents, such
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases20.9.2019 15:00:00 EEST | Press release
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases. In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom